PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease

This publication has 38 references indexed in Scilit:

• A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome
  New England Journal of Medicine, 2003
• Novel translocations that disrupt the platelet‐derived growth factor receptor β (PDGFRB) gene in BCR–ABL‐negative chronic myeloproliferative disorders
  British Journal of Haematology, 2003
• Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate
  Leukemia Research, 2002
• Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta
  New England Journal of Medicine, 2002
• Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
  Nature Reviews Drug Discovery, 2002
• The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA
  Human Molecular Genetics, 2002
• Protein kinases — the major drug targets of the twenty-first century?
  Nature Reviews Drug Discovery, 2002
• Induction of Chronic Myelogenous Leukemia in Mice by the P210 ^bcr/abl Gene of the Philadelphia Chromosome
  Science, 1990
• Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.
  Proceedings of the National Academy of Sciences, 1988
• THE HYPEREOSINOPHILIC SYNDROME
  Medicine, 1975